Drugs acting on cardiovascular (CV) prevention are, by definition, interconnected with age-induced arterial changes. However, this question has been poorly investigated along long-term treatment. This goal requires a major prerequisite: to determine statistical links associating age-induced changes in arterial stiffness and wave reflections with drug classes acting on CV prevention. We studied 347 subjects where CV prevention involved hypertension, diabetes mellitus and hypercholesterolaemia; and included six drug classes: diuretics, b-blocking agents, angiotensin II (ANGII) and calcium-channel (CCB) blockers, insulin therapy and statins. For each class, the total population was divided into two subgroups according to the presence or absence of the corresponding class. Statistical comparisons between subgroups involved brachial and central blood pressure measurements, aortic pulse wave velocity (PWV), augmentation index (AIx), used as a marker of wave reflections. Non-invasive measurements included tonometry and pulse wave analysis. Appropriate adjustments indicated among results the respective role of age, sex, mean blood pressure (MBP), standard risk factors and other confounding variables. CCB and statins did not exhibit statistical association with PWV or AIx. b-Blocking agents were significantly linked with heart rate reduction and resulting increase in AIx and central pulse pressure (PP). Increased PWV independent of age, MBP, CV risk factors were noticed under diuretics, ANGII blockers and insulin, pointing to intrinsic modifications of the arterial wall. Treatment of CV prevention involves alterations of the arterial wall depending on drug class. b-Blocking agents and insulin are associated with the higher increases of central PP.
Introduction
Drugs used in cardiovascular (CV) prevention involve the treatment of at least three risk factors: hypertension, diabetes mellitus and hypercholesterolaemia. The duration of such a chronic drug therapy may exceed 30-50 years. From this simple observation, important connections are expected to occur during the lifespan, associating at least two different factors: the development of vascular aging 1 and drugs chronically used during CV prevention.
The study of such connections may require repeated non-invasive haemodynamic measurements during the life. Thus, several questions are important to discuss before establishing a specific protocol on this clinical problem.
The Reason study 2 has recently shown that, before a 1-year follow-up of antihypertensive treatment, it is possible to predict the level of systolic blood pressure (SBP) under therapy on the basis of three parameters: the baseline SBP, 2 the pretreatment aortic stiffness and the selected class of used pharmacological agent. These parameters, together with previously published cross-sectional data on this therapeutic subject, indicate that two important prerequisites are needed before investigating the relationship between vascular aging and drug classes of CV prevention. First, because vascular aging predominates on central and not peripheral arteries, 1 simultaneous measurements of both brachial (peripheral) and carotid (central) SBP and pulse pressure (PP) are required, together with the two major determinants directly associated with vascular aging: arterial stiffness and wave reflections. Second, it is important to develop primarily an observational study relating the possible statistical links between parameters characterizing vascular aging (arterial stiffness and wave reflection), and the drug classes to be used for CV prevention. Thus, a cross-sectional design in chronically treated (8-10 months) 3 subjects may help to predict very early unexpected CV changes on this topic.
The purpose of this study was, in a population submitted to chronic CV drug prevention, to determine the statistical links between the haemodynamic characteristics of arterial aging and drug classes used during chronic CV prevention. Here, the investigation was limited to three CV risk factors: hypertension, diabetes mellitus and hypercholesterolaemia. Six classes of drug treatment were analysed: diuretics, b-blocking agents, renin-angiotensin (ANGII) blockers, calcium-channel blockers (CCB), chronic insulin treatment and/or oral antidiabetic agents, finally, lipid lowering drugs.
Materials and methods

Patients
From November 2006 to November 2008 B450 consecutive patients entered the Department of Internal Medicine of Hotel-Dieu Hospital (Paris, France) for a CV examination, in relation with the presence of one or several risk factors involving high blood pressure (BP), smoking, dyslipidemia, diabetes mellitus or a family history of premature CV disease. For this study, only subjects with sustained essential hypertension, all treated for at least 8 months (mean value: 12±4 months), and having both brachial and carotid BP measurements, were selected on the basis of previously described criteria excluding secondary forms of hypertension. 4 Normal brachial arterial BP was defined as SBP o140 mm Hg and diastolic blood pressure (DBP) o90 mm Hg. High brachial artery BP was defined as SBP X140 mm Hg and/or DBP X90 mm Hg. Measurements were determined by arm cuff and mercury sphygmomanometry in the supine position as an average of at least three casual determinations, during the previous 2 months. Subjects with a history of congestive heart failure, valvular heart disease or renal insufficiency (defined by a serum creatinine level 4130 mmol l
À1
) were not included in the study. Thus, the investigation was performed in 347 subjects (53% men) aged between 19 and 94 years (mean: 59±14 years, ±1 s.d.). Mean body mass index (BMI) was 28 ± 5 kg m
À2
. Antihypertensive drug treatment included diuretics (45% subjects involving 40% thiazide diuretics, the remaining being composed of spironolactone and/or furosemide), b-blocking agents (29%), ANGII blockers (50%, including either angiotensin-converting enzyme inhibitor (ACEI) or AT1 receptor blocker (ARB) but never their association), CCB (48%), in bi-or tri-therapy or more.
Information compiled from a questionnaire filled out at study inclusion involved sex, age, weight and height, BMI, family (first-degree relatives) history of premature CV events (at o55 years of age in men and o60 years in women), personal history of diabetes mellitus, dyslipidemia, smoking habits, previous diseases and use of medications. From the clinical questionnaire and the data obtained during hospitalization, metabolic risk factor (mrf) were quantified as plasma cholesterol X5.7 mmol l À1 , triglycerides X1.69 mmol l À1 , high-density lipoprotein cholesterol o1.04/1.29 mmol l À1 (men/women) and plasma glucose X7 mmol l À1 . Metabolic syndrome (MS) was defined according to the metabolic syndrome criteria. 5 For the definition of CV events, the usual characteristics were used according to the International Classification of Diseases (nineth revision) for coronary heart disease, cerebrovascular disease, peripheral vascular disease and abdominal aortic aneurysm. Dyslipidemia was defined by a total/high-density lipoprotein cholesterol ratio 45 or by the use of a hypocholesterolemic drug. Anticholesterolemic agents were given in 43% subjects. Diabetes mellitus was defined as a fasting glycemia 47 mmol l À1 or by the use of oral antidiabetic agents. These drugs were given in 18% subjects. Twenty-four percent of subjects were under insulin treatment, as a consequence of a lack of effectiveness of oral antidiabetic agents (plasma glucose 47 mmol l À1 ). The investigation was performed at 9 AM after overnight fasting. Blood samples were withdrawn for determinations of plasma glucose, total and highdensity lipoprotein cholesterol and creatinine. 4 Informed consent was obtained from all the participants after a detailed description of the procedure. All subjects were chronically treated since at least 8 months (mean value: 12±4 months) and had determinations of brachial and carotid BP, heart rate (HR) and aortic pulse wave velocity (PWV) without discontinuation of treatment.
Brachial and carotid BP and HR measurements
Casual brachial BP and HR were measured by OMRON 705IT (HEM-759E) 6 sphygmomanometry and electrocardiography (using 12 leads) in the supine position after 10 min rest. One physician performed three right consecutive BP measurements, and the average of these three values was used for data analysis. Brachial artery PP was calculated as brachial SBP-DBP.
Carotid BP was measured using applanation tonometry. 7 Because the carotid PP is known to be physiologically lower than brachial PP for the same mean blood pressure (MBP), common carotid artery and radial artery pressure waveforms were recorded non-invasively by applanation tonometry with the SphygmoCor system (AtCor Medical, Sydney, Australia). [8] [9] [10] Although SBP and PP are known to increase physiologically and significantly (8-12 mm Hg) from central to peripheral arteries, falls in DBP or MBP from the ascending aorta to the radial artery do not exceed 2-3 mm Hg. [9] [10] [11] Therefore, the carotid pressure wave was calibrated assuming that radial and carotid DBP and MBP were nearly equal. The MBP of the carotid pressure wave, computed from the area measurement of the wave in the corresponding heart period, was taken as equal to brachial MBP. 12 The amplitude of the carotid pressure wave was computed from DBP and the position of MBP on the pressure wave, and the carotid PP was calculated. The augmentation index (AIx), a marker of the alteration of the incident wave by the amplitude and timing of wave reflection, was calculated from the carotid BP curve according to standard methods. 13 The SBP or PP amplification was calculated as carotid PP (or SBP)/brachial PP (or SBP). The reproducibility of these measurements has previously been established in detail elsewhere.
8,10
Determination of aortic PWV Carotid-femoral (aortic) PWV was measured using the Sphygmocor device (AtCor Medical). The technical characteristics of this device have been described previously 8, 10, 13, 14 and indicate inter-and intra-observer repeatability coefficient values X0.9. The basic principle of PWV measurement is that the pressure pulse generated by ventricular ejection is propagated along the arterial tree at a speed determined by the geometric and elastic properties of the arterial wall. 13 The PWV is calculated from measurement of pulse transit time and the distance travelled by the pulse between two recording sites, according to the following formula: PWV (m s À1 ) ¼ Distance (m)/Transit time (s). Carotid-femoral PWV is calculated from the time delay between the recorded proximal (carotid) and distal (femoral) foot waves, and the superficially measured distance separating the respective transducers. In our study, PWV was calculated as the mean of 10 s of consecutive pressure waveforms during at least a complete respiratory cycle.
Statistical analysis
Quantitative data were expressed as mean values± 1 s.d. when adjusted for one or several of the different studied parameters. Qualitative data were expressed as percentage of total of cases present in each modality. A P-value p0.05 was considered significant. Analyses were performed with SAS software version 6.7 (SAS Institute, Cary, NC, USA) under Windows 2000 (Microsoft, Redmond, WA, USA).
For continuous variables, we used analysis of variance/analysis of covariance provided by GLM SAS procedure with one or two factors, followed by the F test for means and important interactions, and eventually adjusted to one or several pertinent parameters (see later). When necessary we estimated the difference between means and indicated the resulting P-value. For qualitative variables, we used the khi-2 test given by logistic procedure for qualitative variables.
The study included: (i) antihypertensive agents divided into four classes (diuretics, b-blockers, ANGII blockers and CCB blockers); (ii) antidiabetic agents with or without insulin treatment; (iii) lipid lowering agents, here including only statins (fibrates were absent of this group of subjects). The same total population (n ¼ 347) was divided six times into two groups according to the presence or absence of diuretics, b-blocking agents, ANGII blockers, CCB blockers, insulin treatment with or without oral antidiabetic agents and statin treatment. For each drug class, comparison of mean values was done between the group 'yes' and 'no' according to classical methods. The comparison study involved crude and adjusted (adj) parameters introduced constantly in the same order: adj 1: age, sex; adj 2: add HR; adj 3: add MBP; adj 4-6: add successively smoking status (4), mrf (5) and BMI (6) . Other adjustments were done further, particularly regarding diabetes mellitus (plasma glucose; HbA1c; presence of insulin treatment) or ANGII blockade (including ACEI or ARB, but not their association).
Stepwise multiple regressions were performed using standard methods. Table 1 summarizes the description of the totality of the studied population (n ¼ 347) as well as the subdivision into two subgroups involving presence or absence of MS. After age and sex adjustments, subjects with MS differed from non-MS subjects not only by BMI, waist circumference, mrf and brachial BP values, but also by presence of proteinuria and reduced AIx and carotid PP/brachial PP. Central SBP and PP and PWV did not differ significantly between the two subgroups. Table 2 summarizes the studied central carotid parameters divided into two groups, with and without the corresponding class of drugs, and the corresponding P-value of each given studied adjustment.
Results
The two subgroups classified as being with and without diuretic treatment are indicated in first line of Table 2 . After adjustment to age and sex, the two subgroups differed by significantly higher values in waist circumference, incidence of MS, plasma creatinine and PWV in subjects under diuretic treatment. The increased PWV under diuretic treatment continued to differ from that of the control group after adjustment to HR, MBP, smoking status, mrf and BMI (or waist circumference). The significant increase in PWV under diuretic treatment remained unmodified when the thiazide diuretic subgroup was studied alone but not when the non-thiazide subgroup (that is, composed of furosemide and/or spironolactone) was studied alone (data not shown). Adjustment of plasma sodium, potassium and creatinine do not interfere when the thiazide results are investigated. In contrast, adjustment to AT1 ARB (but not to ACEI) abolishes the increased PWV under thiazide treatment (Figure 1) . Table 2 indicates in second line the two subgroups classified as being with and without b-blocking agents. After adjustments of age and sex, the two subgroups differed significantly by reduced HR, increased central PP, AIx and carotid PP/brachial PP ratio in patients under b-blocking agents. Using stepwise multiple regression, factors influencing AIx in the overall population were only reduced HR (and independently, presence of b-blocking agent), increased MBP and mostly reduction of BMI. Table 2 indicates in third line the two subgroups classified as being with and without ANGII blockers, whether ACEI or ARB are used. After adjustment to age and sex, the two subgroups differed significantly by higher values of BMI, plasma glucose, HbA1c, plasma creatinine and PWV in subjects under ANGII blockade. Increased PWV under ANGII blockade remained significant (by comparison with their controls) after adjustment to HR, MBP, smoking, mrf and BMI, but was abolished after adjustment to HbA1c (and not to plasma glucose or insulin treatment) (Figure 2 ). Factors influencing PWV in the overall population were age, sex, MBP and HR, and mostly HbA1c level and presence of a thiazide diuretic compound (Table 3) .
In contrast with ANGII blockers, the CCB subgroup did not differ from the subgroup with no CCB (data not shown). In particular, crude or adjusted PWV and AIx never differed between the two subgroups. Table 2 indicates in fourth line the two subgroups classified as being with and without chronic insulin treatment. After adjustment to age and sex, the two subgroups differed significantly by increased values of BMI, plasma glucose, HbA1c, plasma creatinine and proteinuria in subjects under insulin treatment. Increased central PP and PWV under insulin (Table 4 ). In the same population, factors associated to brachial PP were only age, PWV, presence of b-blocking agents, plasma triglycerides and smoking status. Table 2 indicates in fifth line the two subgroups classified as with or without statin treatment. After Abbreviations: b, b blocker; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HR, heart rate; MBP, mean blood pressure; mrf: metabolic risk factor; PP, pulse pressure; PWV, pulse wave velocity; SBP, systolic blood pressure.
adjustment to age and sex, the two subgroups differed significantly by lower values of highdensity lipoprotein cholesterol and increased values of waist circumference, plasma glucose, HbA1c and proteinuria under statin treatment, but did not differ in terms of PWV and AIx. A significantly lower carotid PP/brachial PP ratio was observed under statin (by comparison with controls) but disappeared after adjustment to mrf and/or BMI.
Comments
In 347 subjects under chronic CV prevention, this study showed specific statistical links between drug classes and two major markers of vascular aging: arterial stiffness and wave reflections. First, no statistical link was observed with two agents: CCB and statins. Second, arterial stiffness was positively associated with presence of thiazide diuretics, ANGII blockers and insulin treatment, whereas wave reflections (AIx) were significantly associated only with the use of b-blocking agents. Taken together, these findings suggest that, with age and resulting arterial changes, significant connections may be observed between PWV or AIx and several drug classes acting on CV prevention. This investigation was performed using two parameters considered as the 'gold standard' of vascular aging: PWV and AIx. 15 All determinations of brachial and central PP were performed in parallel at two arterial sites: the brachial artery and the carotid artery, which are differently influenced by age. An important particularity of the methodology was that all measurements required a calibration of the brachial artery blood pressure curve, which is frequently difficult to perform. 16 On the other hand, it is worth to note that the determination of the carotid PP/brachial PP ratio does not need this calibration and thus, is easier to obtain. 17 The major difficulty of this work was to be totally observational: no cause to effect relationship could be investigated. Finally, because of the relatively small number of subjects, statistical interactions were difficult to use. Nevertheless, the statistical results involved several findings, in relation with the use of adequate adjustments. First, results were adjusted to age, sex, HR and MBP, so that the role of these parameters could be primarily excluded from the observed changes of arterial stiffness or wave reflections. Second, the role of smoking and metabolic factors could be excluded on the basis of BMI, waist circumference, smoking status and mrf adjustments. Third, the role of glucose disorders was investigated on the basis of study of plasma glucose, HbA1c and presence of antidiabetic treatments. Finally, the renin-angiotensin system was explored through adjustments to ANGII blockade and potentially to angiotensin ARB or ACEI. Diuretics are the most classical agents used in hypertension and CV prevention. In the past, controlled clinical studies never showed that diuretic treatment modified arterial stiffness or wave reflections and such studies were frequently of short duration. 18 To our knowledge, the present report is the first indicating a significant link between thiazide diuretic and increased aortic stiffness, suggesting a possible role of plasma electrolytes as calcium. 19 Note that increased PWV was independent of adjustment to age, sex and MBPs, indicating the presence of intrinsic modifications of the large artery wall under thiazide treatment alone. Nevertheless, the finding of ARB adjustment also indicates the well-established links between renin-angiotensinaldosterone system and thiazide therapy. 20 The role of b-blocking agents on central PP and wave reflections has been extensively investigated in recent years by the Reason 21 and Café 22 studies. Reduced HR is responsible for a shift of the backward pressure wave from diastole to systole, thus producing an increase in central SBP and PP. This finding, which is responsible for the presence of increased AIx and peak SBP in the present investigation, is not necessarily observed with all b-blocking agents, particularly those associated with vasodilating properties. 23, 24 In addition, the multiple regression analysis of the overall population indicates a possible statistical link between AIx and both BMI and the presence of b-receptor blocking agent.
In contrast with CCB, ANGII blockers exhibited a major increase in PWV independent of age, MBP and standard CV risk factors, thus indicating intrinsic modifications of the arterial wall. Such alterations cannot be due to BP alone but rather to diabetes mellitus, whether considered alone or in association with hypertension. This finding can be surprising because both ACEI and ARB are known to potentially reduce PWV. 25, 26 However, in our study, the multiple regression analysis of the overall population showed that the population involved 50.9% diabetic subjects when ANGII blockade was present and only 18.7% diabetic subjects when ANGII blockade was absent. Clearly, the study of the overall population might suggest that, in agreement with this high incidence of diabetic subjects, the increase of PWV is more likely related to the role of HbA1c (that is, a situation related to diabetes mellitus and its treatment) than to ANGII blockade and its treatment by hypertension. However, prospective studies comparing diabetic and non-diabetic subjects should be advisable to detect better the stiffness changes.
As we indicated earlier, subjects under insulin treatment were of particular gravity, associating increase of body weight and metabolic disorders (mrf), proteinuria and reduced renal function. Increases of central PP and PWV, but not increase of brachial PP, were present even after adjustment for age, sex, HR and MBP. Central PP, but not PWV, was attenuated after adjustment to ARB. No other adjustment of the studied parameters could modify PWV in the present population. The literature indicates that, in subjects with hypertension and diabetes mellitus, the enhanced PWV may be reduced only under acute administration of ALT-711, a collagen crosslink breaker related to the formation of glycation end-products. 27 In the multiple regression analysis of our study (Table 2) , central PP was positively correlated with the presence of both b-blocking agents and insulin administration.
This study has shown the frequency of significant statistical association of PWV and/or AIx with six different classes of drugs, which are widely used during CV prevention. Several observations can be drawn, based on the consistency of the results. First, it is clear that there are important differences between the classes of antihypertensive drugs, regarding the differential effect of drugs on arterial wall properties. Second, it seems that the newer antihypertensive drugs (ANGII blockers, CCBs) might have a more beneficial effect on the vessel wall than the older drugs (diuretics and beta blocking agents). The main common feature between these classes of drugs appears to be their arterial dilating capacity and their ability to reduce pressure wave reflections, as expressed by augmentation index. Third, there is compelling evidence regarding the detrimental effect of b-blocking agents (mainly atenolol) on central BP. Whether, newer b-blocking agents with vasodilating properties are de-voided of these effects remains to be proven. The above conclusions highlight two crucial issues: (i) the need for more data derived from wellcontrolled short and long-term studies that will further clarify the effect of antihypertensive drugs on vessel wall and BP amplification; (ii) the urgent need of clinical trials focusing on central haemodynamics. Only the results of such studies may challenge (or not) the current antihypertensive treatment strategies which are based on brachial BP.
What is known about this topic K Drugs acting on cardiovascular (CV) prevention may interact with age-induced arterial changes such as those produced by PWV and wave reflection. K This question has been poorly investigated during longterm treatment, particularly in the elderly in the presence of associated diabetes, hypertension and dyslipidemia.
What the study adds K CCB and statins do not exhibit any statistical association with PWV or AIx. K Beta-blocking agents are significantly linked with heart rate reduction and resulting changes in wave reflection and central PP. K Increased PWV independent of age, MBP, CV risk factors are noticed under diuretics, ANGII blocker and insulin, pointing to the presence of intrinsic modifications of the arterial wall. K Treatment of CV prevention involves alterations of the arterial wall depending on drug class. Beta blocking agents and insulin are the drugs associated with the higher increase of central PP.
